A plan that passed six practices but only partly passed two
GAO reviewed FDA's modernization strategy against eight leading practices. The plan fully addressed six and partially addressed two. It omitted high-level project costs or budget estimates and the human-capital resources needed to deliver the work.
That distinction matters: the audit did not call the entire strategy deficient. It found that a credible direction lacked enough cost and workforce detail to show whether the agency could execute it.
| Status | Investments |
|---|---|
| Linked to related projects, milestones and risks | 9 |
| Not fully linked | 8 |
| Total ongoing major investments | 17 |
Nearly half the major portfolio lacked complete connective tissue
FDA had 17 ongoing major IT investments. GAO found that nine connected the investment to related projects with milestones and risks; eight did not fully do so. The missing links make it harder for managers and Congress to tell which project delay threatens which strategic goal.
A linkage is not proof that a system works, and a missing link is not proof that money was wasted. It is a portfolio-governance control: decision-makers need to see dependencies before a delayed project creates a chain reaction.
HHS agreed with three recommendations
GAO recommended that FDA add cost and workforce information and strengthen the connection between major investments and the strategy. The Department of Health and Human Services concurred with all three recommendations.
This analysis counted the linked and not-fully-linked investments and separated plan quality from delivery evidence. The next accountability record is a revised strategy showing dollar ranges, responsible staff, milestones and risk ownership—not simply a statement that modernization remains a priority.
